DB05765InvestigationalSmall molecule
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the... The Company determined that the program was not meeting their expected primary and exploratory objectives.
- Primary indication
- Investigated for use/treatment in actinic keratosis.Curator reviewed
- Code names
- ATX-201
What you can answer from here — as of April 23, 2025
Which companies are running trials of ATX-201, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account